drugset / Trial / NCT06633055
A Phase I Clinical Trial of JH013 Injection
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a phase I clinical trial with a single dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JH013 injection in healthy subjects
Timeline
- Start
- 2024-10-31
- Primary completion
- 2025-06-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JH013 | Unknown | 75 mg | Subcutaneous |
| Subject | JH013 | Unknown | 150 mg | Subcutaneous |
| Subject | JH013 | Unknown | 300 mg | Subcutaneous |
| Subject | JH013 | Unknown | 500 mg | Subcutaneous |
Indications
No indication recorded.